검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan-hziy) Gilead / Immunomedics·Metastatic Urothelial Cancer ORR 34.3% |
|---|---|
Overview Program | Sacituzumab Govitecan-hziy |
Overview Company | Gilead / Immunomedics |
Overview Modality | ADC |
Overview Target | Metastatic Urothelial Cancer |
Overview Indication | Metastatic Urothelial Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen |
MoA Biomarker | Trop2 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine.. Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. A… |
Clinical Primary efficacy | ORR 34.3% |
Clinical ORR | 33.3% |
Clinical PFS | 5.6 |
Clinical OS | 13.0 |
Clinical Result source | ClinicalTrials.gov NCT01631552 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan-hziy) Gilead / Immunomedics·Metastatic Urothelial Cancer ORR 34.3% |
|---|---|
Overview Program | Sacituzumab Govitecan-hziy |
Overview Company | Gilead / Immunomedics |
Overview Modality | ADC |
Overview Target | Metastatic Urothelial Cancer |
Overview Indication | Metastatic Urothelial Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen |
MoA Biomarker | Trop2 expression |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine.. Advanced triple-negative breast cancer (TNBC) has poorer outcomes due to its aggressive behavior and restricted therapeutic options. While therapies like checkpoint inhibitors and PARP inhibitors offer some benefits, chemotherapy remains ineffective beyond the first line of treatment. A… |
Clinical Primary efficacy | ORR 34.3% |
Clinical ORR | 33.3% |
Clinical PFS | 5.6 |
Clinical OS | 13.0 |
Clinical Result source | ClinicalTrials.gov NCT01631552 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교